Background. In patients with chronic kidney disease, vascular calcification contributes to increased cardiovascular (CV) morbidity and mortality. CV risk remains high after successful renal transplantation. Osteoprotegerin (OPG) is a glycoprotein, involved in the regulation of the vascular calcification process. Previous studies have shown that elevated OPG is predictive of mortality in high-risk populations. The aim of this study was to investigate the prognostic value of OPG for graft function, CV events and all-cause death, in a large transplant cohort. Methods. OPG was measured at baseline in renal transplant recipients enrolled in the Assessment of Lescol in Renal Transplantation (ALERT) study, a randomized placebocontrolled intervention study comparing fluvastatin and placebo. Patients were followed for 6.7 years with evaluation of pre-specified end points, graft loss, graft function, CV events and death. Results. OPG was analysed in 1889 renal transplant recipients, with a mean value of 4.69 6 1.85 pg/L. The number of renal and CV events increased by quartiles of OPG. In the multivariate analysis, OPG in the fourth as compared to first quartile was an independent predictor of graft failure or doubling of serum creatinine [hazard ratio (HR) 2.20 (1.56-3.11), P < 0.001], major CV events , P < 0.001], cardiac mortality ), P ¼ 0.007] and all-cause mortality [HR 2.31 (1.53-3.49), P < 0.001]. Conclusion. In a large cohort of kidney transplant patients with long-term follow-up, OPG was independently associated with renal events, CV events and mortality.
Introduction
Chronic kidney disease (CKD) is associated with disturbances in bone metabolism, resulting in mineral bone disorder and affection of the vasculature with development of vascular calcification [1, 2] . Vascular calcification is common in CKD and is associated with significant cardiovascular (CV) morbidity and mortality [3] . Kidney transplantation reduces CV risk to some extent, but CV disease still remains the leading cause of death in renal transplant recipients [4] .
In recent years, data have emerged regarding the interaction between bone disease and vascular calcification indicating mechanisms of calcification [2] , which go beyond secondary hyperparathyroidism, calcium and phosphate metabolism. One of the important actors in the vascular calcification process is osteoprotegerin (OPG), a glycoprotein [5] , which acts as a soluble decoy receptor for the tumour necrosis factor family [1] . Animal studies have demonstrated that OPG-deficient mice develop both severe osteoporosis and vascular calcification [6] . OPG affects bone formation and resorption and is present not only in bone but also in other tissues such as the vasculature, heart and kidney [7] . In addition, several studies have demonstrated that OPG is incorporated in atherosclerotic plaques [8, 9] . Conversely, elevated plasma levels of OPG are associated with increased mortality in high-risk patients with diabetes [10] , heart failure [11] and acute coronary syndrome [12] as well as in the general population [13] . However, the exact mechanism for regulation of OPG in plasma and the presence of OPG in vascular and endothelial cells still remains unclear [14] .
In patients with CKD, levels of OPG are generally elevated [15] and levels of OPG correlate with the degree of vascular calcification [16] . Some evidence exists that levels of OPG are inversely related to kidney function [15] , with subsequent decrease of OPG levels after renal transplantation [17] . Until now, only few data exist regarding the prognostic importance of OPG levels in renal transplant recipients [18] .
The aim of this study was to examine the association between OPG levels, renal outcomes, CV morbidity and mortality in a large cohort of renal transplant recipients.
Materials and methods

Study design
The design of the Assessment of Lescol in Renal Transplantation (ALERT) study and baseline data have previously been described [19, 20] . The ALERT study was a randomized placebo-controlled intervention study comparing the effect of fluvastatin versus placebo on renal and CV end points. In the initial study, 2102 renal transplant recipients were enrolled and followed for a mean of 5.1 years. Patients included were between 30 and 75 years, had received a kidney transplant at least 6 months before randomization and had a baseline serum cholesterol between 4 and 9 mmol/L. Exclusion criteria were ongoing statin therapy, familiar hypercholesterolaemia, predicted life expectancy <1 year or rejection episodes within 3 months before screening. After the core study, 1652 patients were followed up in an open-label extension study, in which they received 80 mg fluvastatin for 2 years, with a mean total follow-up of 6.7 years. Of the 1889 patients with available OPG at baseline, 1072 were among the 1652 patients followed in the extension study.
Outcome definitions
Major adverse cardiovascular events (MACE) were defined as non-fatal myocardial infarction, cardiac death or coronary intervention procedure. Renal events were defined as time to graft failure or doubling of serum creatinine (GFDSC). An independent clinical end point committee validated all end points.
OPG analysis
OPG was measured in serum at baseline by enzyme-linked immunosorbent assays (Biomedica GmbH, Vienna, Austria).
Ethics
The study was performed according to the Declaration of Helsinki, approved by the ethics committee and all patients gave signed informed consent. The study was monitored according to Good Clinical Practice guidelines.
Statistical analysis
In an initial analysis, the placebo and fluvastatin group were analysed separately. However, since the treatment arms showed no significant heterogeneity regarding OPG and end points, we report on the pooled patient population. OPG was analysed by Cox proportional hazard model using the enter method. Explanatory variables were entered into the regression based on clinical knowledge and published literature. OPG quartiles are reported with the first quartile as reference. Adjusted survival curves were drawn from the multivariate models stratifying on quartiles of OPG. SPSS version 17.0 (SPSS Inc., Chicago, IL) was used for statistical analysis.
Results
Baseline data
OPG analysis was available in 1889 participants. Mean OPG was 4.69 AE 1.85 pg/L. For this post hoc analysis, we divided patients into four groups according to quartiles of OPG. Patients with higher OPG were older and had higher systolic blood pressure (BP) and creatinine. In addition, patients with high OPG had higher phosphate and parathyroid hormone (PTH) levels. Demographic data are presented in Table 1 .
Outcomes
Incidence rates for renal events (GFDSC, n ¼ 413), CV events (MACE, n ¼ 285), cardiac mortality (n ¼ 118) and all-cause mortality (n ¼ 350) are presented in Figure 1 . For all end points, the incidence rates increased according to quartiles of OPG.
Risk factor analysis
We performed a multivariate analysis using pre-specified covariates for GFDSC: age, gender, treatment group (fluvastatin/placebo), pulse pressure (systolic BP-diastolic BP), diabetes, current smoking, TTRRT (total time in renal replacement therapy), creatinine, proteinuria, PTH. In the multivariate analysis for MACE, cardiac mortality and all-cause mortality, we used the following variables: age, gender, treatment group, pulse pressure, coronary heart disease, low-density lipoprotein cholesterol, current smoking, creatinine, diabetes and PTH. OPG remained a significant predictor for GFDSC, MACE, cardiac mortality and all-cause mortality, also after adjusting for the abovementioned covariates. Multivariate adjusted survival curves are shown in Figure 2 (GFDSC) and Figure 3 (all-cause mortality). Unadjusted and adjusted hazard ratios (HRs) are presented in Table 2 . Log-transformed high-sensitive C-reactive protein was added as a covariate in the multivariate models without any substantial change in HR for OPG (i.e. <10% change, data not shown), except for cardiac mortality where the HR for OPG increased by~15%. TTRRT was also included as a covariate in the multivariate models for MACE, cardiac and all-cause mortality without any substantial change in HR for OPG (data not shown). We also assessed the optimal cut-off points for OPG for clinical end points; 4.51 pg/L (sensitivity 66 and specificity 56) for MACE, 4.48 pg/L (sensitivity 61 and specificity 55) for graft loss or doubling serum creatinine and 4.73 pg/L (sensitivity 66 and specificity 64) for all-cause mortality.
Discussion
In this large cohort of renal transplant recipients, OPG was associated with renal and CV events, cardiac mortality and with all-cause mortality. These results are in line with previous studies in other populations where OPG consequently has been a prognostic factor of CV events and all-cause mortality [21] .
OPG as a prognostic marker
Elevated OPG has been linked to excess mortality in population-based studies [22, 23] , in high-risk patients with diabetes [10] , acute coronary syndrome [12] or heart failure [18] . OPG as a predictor of CV disease and mortality have recently been summarized in an extensive review by Venuraju et al. [7] . In patients with CKD, several small cohort studies have demonstrated that elevated OPG levels predict CV and all-cause mortality [16, 24, 25] . Only one previous study has examined the prognostic value of OPG in renal transplant recipients. In a relatively small cohort of 173 renal transplantation recipients, Hjelmesaeth et al. [18] showed that high OPG levels at baseline was associated with all-cause mortality and CV death. However, the authors found no association between OPG levels and graft loss. In contrast, in the present study, we found a clear association between elevated OPG and graft loss. A likely explanation for this discrepancy is the small size of the study and few renal end points in the earlier trial.
OPG and calcification
There might be several possible explanations for a correlation between elevated OPG, CV events and mortality. In the present study, we did not address plaque burden or calcification score, but one explanation for the association between OPG, mortality and CV events could be that OPG is a marker for extensive calcification. In patients with diabetes, coronary artery calcification scores are associated with higher levels of OPG [13] and in patients with CKD, elevated OPG predicts coronary calcification [26] and calcification of the femoral artery [24] . In one study of renal transplant recipients, elevated OPG was associated with progression of coronary artery calcification, at 1 year post-transplantation [27] . Both in patients with CKD and in renal transplant recipients [28] , extensive calcification predicts CV events and all-cause mortality.
OPG marker or actor?
It still remains unclear whether OPG merely is a marker for atherosclerosis or an active component in the atherosclerotic process. OPG is expressed in atherosclerotic plaques, both in patients with carotid atherosclerosis [8] and in patients with unstable coronary plaques [9] . Thus, one of the possible explanations for the relation between elevated OPG, MACE and death might be that elevated OPG levels are a marker of an ongoing process in the atherosclerotic plaque. Animal studies have demonstrated that OPGdeficient mice develop severe osteoporosis, and vascular calcification and inactivation of OPG in Apo E1/À mice inhibits plaque progression [9] . In addition, one animal study demonstrated that OPG injections were able to alter the calcification process although calcification was not reversed [29] . Thus, the existing data suggests that OPG may be an actor/regulator of the atherosclerotic process rather than merely an inactive marker of atherosclerosis. Variables are shown as mean 6 SD or frequency (%). CHD, coronary heart disease; ACE/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; ASA, acetylsalicylic acid; LDL cholesterol, low-density lipoprotein cholesterol. 
OPG and the kidney
Data from the Framingham Offspring cohort showed that levels of OPG were increased in CKD patients versus those without CKD [30] . In this study, OPG levels were also correlated to albuminuria. OPG levels are generally elevated in patients with CKD [15] and after successful renal transplantation, there is a decrease in OPG levels [17, 31] . Therefore, kidney function per se might be related to levels of OPG since it is not known whether OPG is metabolized or cleared by the kidney. Until now, there have been few data regarding levels of OPG and progression of CKD. In one study of 397 patients with diabetes, elevated OPG was associated with progression to end-stage renal disease, also after adjusting for kidney function and albuminuria [10] . This is consistent with our results showing a clear association between OPG levels, doubling of serum creatinine or graft loss.
OPG and intervention
Until now, two small intervention studies have investigated the effects of statins on levels of OPG. In 18 patients with type 2 diabetes, Nellemann et al. [32] showed that treatment with 10 mg of simvastatin, compared to placebo, significantly reduced OPG after 18 weeks. Dimitrow et al. [33] treated 33 patients with aortic sclerosis/stenosis with atorvastatin and showed a reduction in OPG levels after treatment. This study did not have a control group. These findings might be of interest, as they may show a possible link between the atherosclerosis process, OPG and statins. In the present study, we did not assess OPG levels after treatment with fluvastatin and placebo.
Strengths and limitations
The strengths of this study are that it is performed in a large cohort of renal transplanted patients with a long follow-up time and evaluating pre-specified end points. One limitation is that OPG was restricted to baseline values. However, patients were included at least 6 months after kidney transplantation and were considered stable with regard to kidney function at the time of inclusion. a GFDSC, graft failure or doubling of serum creatinine; Q, quartile. The following variables were used as covariates in the multivariate analysis for GFDSC: age, gender, treatment (fluvastatin/placebo), pulse pressure (systolic BP-diastolic BP), diabetes, current smoking, TTRRT, creatinine, proteinuria, PTH. In the multivariate analysis for MACE, cardiac death and all-cause death, the following variables were used: age, gender, treatment (fluvastatin/placebo), pulse pressure, coronary heart disease, lowdensity lipoprotein cholesterol, current smoking, creatinine, diabetes and PTH. The lowest OPG quartile is reference for the given HRs and P-values. In parentheses, 95% confidence intervals. Fig. 2 . Graft failure or doubling of serum creatinine in relation to OPG quartiles. Multivariate adjusted survival curve, covariates as described in Table 2 . Fig. 3 . All-cause mortality in relation to OPG quartiles. Multivariate adjusted survival curve, covariates as described in Table 2 .
Conclusion
In a large cohort of renal transplant recipients, we have demonstrated an association between elevated levels of OPG graft loss, CV events, cardiac mortality and all-cause mortality.
